JP4234798B2 - スルホンアミド−置換クロマン、それらの製造法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 - Google Patents
スルホンアミド−置換クロマン、それらの製造法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 Download PDFInfo
- Publication number
- JP4234798B2 JP4234798B2 JP13798497A JP13798497A JP4234798B2 JP 4234798 B2 JP4234798 B2 JP 4234798B2 JP 13798497 A JP13798497 A JP 13798497A JP 13798497 A JP13798497 A JP 13798497A JP 4234798 B2 JP4234798 B2 JP 4234798B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- dimethylchroman
- methyl
- ethylsulfonyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 69
- 238000002360 preparation method Methods 0.000 title description 4
- 230000008569 process Effects 0.000 title description 3
- 150000001843 chromanes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 79
- -1 methoxy, sulfamoyl Chemical group 0.000 claims description 79
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- 125000004432 carbon atom Chemical group C* 0.000 claims description 46
- 229910052801 chlorine Inorganic materials 0.000 claims description 32
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 229910052731 fluorine Inorganic materials 0.000 claims description 28
- 229910052794 bromium Inorganic materials 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910052740 iodine Inorganic materials 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- YKURFHOYVQJKSA-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydrochromen-3-amine Chemical compound C1=CC=C2CC(N)C(C)(C)OC2=C1 YKURFHOYVQJKSA-UHFFFAOYSA-N 0.000 claims description 13
- 229940124530 sulfonamide Drugs 0.000 claims description 13
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 12
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 11
- 150000003456 sulfonamides Chemical class 0.000 claims description 11
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 229910004013 NO 2 Inorganic materials 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 239000011734 sodium Chemical group 0.000 claims description 6
- 238000005804 alkylation reaction Methods 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- GIJPFQQNRIYDEG-UHFFFAOYSA-N NC1C(OC2=C(C1)C=C(C=C2)F)(C)C Chemical compound NC1C(OC2=C(C1)C=C(C=C2)F)(C)C GIJPFQQNRIYDEG-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 229910052700 potassium Chemical group 0.000 claims description 4
- 239000011591 potassium Chemical group 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- MHAOGRMTYIGDML-UHFFFAOYSA-N 3-amino-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile Chemical compound C1=C(C#N)C=C2CC(N)C(C)(C)OC2=C1 MHAOGRMTYIGDML-UHFFFAOYSA-N 0.000 claims description 3
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims description 3
- 238000007336 electrophilic substitution reaction Methods 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000002861 ventricular Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 239000000047 product Substances 0.000 description 59
- 239000000203 mixture Substances 0.000 description 56
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 55
- 239000002904 solvent Substances 0.000 description 53
- 239000002178 crystalline material Substances 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- 239000013078 crystal Substances 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 36
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 36
- 108091006146 Channels Proteins 0.000 description 33
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 238000002844 melting Methods 0.000 description 29
- 230000008018 melting Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 229910000104 sodium hydride Inorganic materials 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000460 chlorine Substances 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 20
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 19
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000009471 action Effects 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- LNDGACQEAYKNOI-UHFFFAOYSA-N 1,1,1-trifluoro-4-iodobutane Chemical compound FC(F)(F)CCCI LNDGACQEAYKNOI-UHFFFAOYSA-N 0.000 description 12
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 11
- UAXWPLCLDSMHRF-UHFFFAOYSA-N 2,2-dimethyl-6-hydroxychroman-4-one Natural products OC1=CC=C2OC(C)(C)CC(=O)C2=C1 UAXWPLCLDSMHRF-UHFFFAOYSA-N 0.000 description 10
- 238000004821 distillation Methods 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 7
- 229910000564 Raney nickel Inorganic materials 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- OHBAWAXGKXWFAZ-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.C1=CC=C2OC(C)(C)CC(N)C2=C1 OHBAWAXGKXWFAZ-UHFFFAOYSA-N 0.000 description 6
- ZCZUDOBLRMXOGV-UHFFFAOYSA-N 2,3-Dihydro-6-methoxy-2,2-dimethyl-4H-1-benzopyran-4-one Chemical compound O1C(C)(C)CC(=O)C2=CC(OC)=CC=C21 ZCZUDOBLRMXOGV-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 0 C*c1c(*(C)C)c(*)c(*)c(C(C)C2)c1OC2(*)*(C)C Chemical compound C*c1c(*(C)C)c(*)c(*)c(C(C)C2)c1OC2(*)*(C)C 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IFUDNQFEYVTYQW-UHFFFAOYSA-N methyl 4-amino-2,2-dimethyl-3,4-dihydrochromene-6-carboxylate Chemical compound O1C(C)(C)CC(N)C2=CC(C(=O)OC)=CC=C21 IFUDNQFEYVTYQW-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 4
- KOFFXZYMDLWRHX-UHFFFAOYSA-N 1-(5-fluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC=C1O KOFFXZYMDLWRHX-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- PLEFHPWZHDJYFJ-UHFFFAOYSA-N 4-amino-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2OC(C)(C)CC(N)C2=C1 PLEFHPWZHDJYFJ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 229960000212 aminophenazone Drugs 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical group 0.000 description 4
- MISFQCBPASYYGV-UHFFFAOYSA-N (4-phenylphenyl) acetate Chemical group C1=CC(OC(=O)C)=CC=C1C1=CC=CC=C1 MISFQCBPASYYGV-UHFFFAOYSA-N 0.000 description 3
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 3
- NBUWNTIATBQVDR-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile Chemical compound N#CC1=CC=C2OC(C)(C)CCC2=C1 NBUWNTIATBQVDR-UHFFFAOYSA-N 0.000 description 3
- FPBXWXGOFQSROI-UHFFFAOYSA-N 3-acetyl-4-hydroxybenzoic acid Chemical compound CC(=O)C1=CC(C(O)=O)=CC=C1O FPBXWXGOFQSROI-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229950004210 cromakalim Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 3
- QXDKURCWIRRHJS-UHFFFAOYSA-N n-(2,2,6-trimethyl-3,4-dihydrochromen-4-yl)ethanesulfonamide Chemical compound C1=C(C)C=C2C(NS(=O)(=O)CC)CC(C)(C)OC2=C1 QXDKURCWIRRHJS-UHFFFAOYSA-N 0.000 description 3
- UNXIXBDISARUMK-UHFFFAOYSA-N n-(7-chloro-6-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)ethanesulfonamide Chemical compound ClC1=C(F)C=C2C(NS(=O)(=O)CC)CC(C)(C)OC2=C1 UNXIXBDISARUMK-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- SJMMFGNAJFFWNL-UHFFFAOYSA-N (2,4-difluorophenyl) acetate Chemical compound CC(=O)OC1=CC=C(F)C=C1F SJMMFGNAJFFWNL-UHFFFAOYSA-N 0.000 description 2
- OSKGYRIYNMZFSJ-UHFFFAOYSA-N (3,4-dichlorophenyl) acetate Chemical compound CC(=O)OC1=CC=C(Cl)C(Cl)=C1 OSKGYRIYNMZFSJ-UHFFFAOYSA-N 0.000 description 2
- SCDFAHSIYYBVTF-UHFFFAOYSA-N (3,4-difluorophenyl) acetate Chemical compound CC(=O)OC1=CC=C(F)C(F)=C1 SCDFAHSIYYBVTF-UHFFFAOYSA-N 0.000 description 2
- IPSIPXOXHRSGTM-UHFFFAOYSA-N (3-chloro-4-fluorophenyl) acetate Chemical compound CC(=O)OC1=CC=C(F)C(Cl)=C1 IPSIPXOXHRSGTM-UHFFFAOYSA-N 0.000 description 2
- HFWBXYDXTXEIIQ-UHFFFAOYSA-N (4-amino-2,2-dimethyl-3,4-dihydrochromen-6-yl) methanesulfonate;hydrochloride Chemical compound Cl.CS(=O)(=O)OC1=CC=C2OC(C)(C)CC(N)C2=C1 HFWBXYDXTXEIIQ-UHFFFAOYSA-N 0.000 description 2
- ANMYMLIUCWWISO-UHFFFAOYSA-N (4-ethylphenyl) acetate Chemical compound CCC1=CC=C(OC(C)=O)C=C1 ANMYMLIUCWWISO-UHFFFAOYSA-N 0.000 description 2
- MCDJUVXLLXTCFP-UHFFFAOYSA-N 1-(3,5-difluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC(F)=C1O MCDJUVXLLXTCFP-UHFFFAOYSA-N 0.000 description 2
- GSTOHKXQBZZTPF-UHFFFAOYSA-N 1-(5-ethyl-2-hydroxyphenyl)ethanone Chemical compound CCC1=CC=C(O)C(C(C)=O)=C1 GSTOHKXQBZZTPF-UHFFFAOYSA-N 0.000 description 2
- MWCLIHHFUUYVDF-UHFFFAOYSA-N 2,2,6-trimethyl-3h-chromen-4-one Chemical compound O1C(C)(C)CC(=O)C2=CC(C)=CC=C21 MWCLIHHFUUYVDF-UHFFFAOYSA-N 0.000 description 2
- DUTNTKTZIQAPGA-UHFFFAOYSA-N 2,2-dimethyl-3h-chromen-4-one Chemical compound C1=CC=C2OC(C)(C)CC(=O)C2=C1 DUTNTKTZIQAPGA-UHFFFAOYSA-N 0.000 description 2
- PTOMGSWLGSRLCK-UHFFFAOYSA-N 2,2-dimethyl-4-oxo-3h-chromene-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2OC(C)(C)CC(=O)C2=C1 PTOMGSWLGSRLCK-UHFFFAOYSA-N 0.000 description 2
- VLBUGUIIJYKNNT-UHFFFAOYSA-N 2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-3h-chromen-4-one Chemical compound FC(F)(F)CCCOC1=CC=C2OC(C)(C)CC(=O)C2=C1 VLBUGUIIJYKNNT-UHFFFAOYSA-N 0.000 description 2
- ONUIVRABQZPZIQ-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-3,4-dihydrochromen-3-amine Chemical compound NC1C(OC2=CC=C(C=C2C1)[N+](=O)[O-])(C)C ONUIVRABQZPZIQ-UHFFFAOYSA-N 0.000 description 2
- QZBUNLDATRRBND-UHFFFAOYSA-N 2,2-dimethyl-6-phenyl-3h-chromen-4-one Chemical compound C=1C=C2OC(C)(C)CC(=O)C2=CC=1C1=CC=CC=C1 QZBUNLDATRRBND-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HBLDKCGIBIGVPC-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-3-ol Chemical class C1=CC=C2CC(O)COC2=C1 HBLDKCGIBIGVPC-UHFFFAOYSA-N 0.000 description 2
- WVOIVMNXIKMNQQ-UHFFFAOYSA-N 4-[dimethylsulfamoyl(methyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile Chemical compound C1=C(C#N)C=C2C(N(C)S(=O)(=O)N(C)C)CC(C)(C)OC2=C1 WVOIVMNXIKMNQQ-UHFFFAOYSA-N 0.000 description 2
- MKQQHQNLVTZYFF-UHFFFAOYSA-N 4-[dimethylsulfamoyl(methyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxamide Chemical compound C1=C(C(N)=O)C=C2C(N(C)S(=O)(=O)N(C)C)CC(C)(C)OC2=C1 MKQQHQNLVTZYFF-UHFFFAOYSA-N 0.000 description 2
- RBXNUZWQGXHBNL-UHFFFAOYSA-N 4-[dimethylsulfamoyl(methyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(N(C)S(=O)(=O)N(C)C)CC(C)(C)OC2=C1 RBXNUZWQGXHBNL-UHFFFAOYSA-N 0.000 description 2
- IIBHQTXJTUSHBK-UHFFFAOYSA-N 4-bromo-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile Chemical compound N#CC1=CC=C2OC(C)(C)CC(Br)C2=C1 IIBHQTXJTUSHBK-UHFFFAOYSA-N 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 2
- VSNPRKDVSQYMPC-UHFFFAOYSA-N 4-hydroxyimino-2,2-dimethyl-3H-chromene-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2OC(C)(C)CC(=NO)C2=C1 VSNPRKDVSQYMPC-UHFFFAOYSA-N 0.000 description 2
- LTWSLRBUUBTDTG-UHFFFAOYSA-N 6,7-dichloro-2,2-dimethyl-3h-chromen-4-one Chemical compound ClC1=C(Cl)C=C2OC(C)(C)CC(=O)C2=C1 LTWSLRBUUBTDTG-UHFFFAOYSA-N 0.000 description 2
- OMWVNQFGCGNZHE-UHFFFAOYSA-N 6,7-dimethoxy-2,2-dimethyl-3h-chromen-4-one Chemical compound O1C(C)(C)CC(=O)C2=C1C=C(OC)C(OC)=C2 OMWVNQFGCGNZHE-UHFFFAOYSA-N 0.000 description 2
- NHXQSAXNVCFRKP-UHFFFAOYSA-N 6,8-difluoro-2,2-dimethyl-3h-chromen-4-one Chemical compound FC1=CC(F)=C2OC(C)(C)CC(=O)C2=C1 NHXQSAXNVCFRKP-UHFFFAOYSA-N 0.000 description 2
- TXFJMSQAYBRSRI-UHFFFAOYSA-N 6-(4-bromophenyl)-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.C=1C=C2OC(C)(C)CC(N)C2=CC=1C1=CC=C(Br)C=C1 TXFJMSQAYBRSRI-UHFFFAOYSA-N 0.000 description 2
- WSLHNSBKXLMKOU-UHFFFAOYSA-N 6-ethyl-2,2-dimethyl-3h-chromen-4-one Chemical compound O1C(C)(C)CC(=O)C2=CC(CC)=CC=C21 WSLHNSBKXLMKOU-UHFFFAOYSA-N 0.000 description 2
- MPJMDEXLUJRBBJ-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3h-chromen-4-one Chemical compound FC1=CC=C2OC(C)(C)CC(=O)C2=C1 MPJMDEXLUJRBBJ-UHFFFAOYSA-N 0.000 description 2
- MZLPOLIBBWRNPP-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-7-pyrrolidin-1-yl-3h-chromen-4-one Chemical compound C1=C2OC(C)(C)CC(=O)C2=CC(F)=C1N1CCCC1 MZLPOLIBBWRNPP-UHFFFAOYSA-N 0.000 description 2
- NKCIUOVMTURVQK-UHFFFAOYSA-N 7-chloro-6-fluoro-2,2-dimethyl-3h-chromen-4-one Chemical compound FC1=C(Cl)C=C2OC(C)(C)CC(=O)C2=C1 NKCIUOVMTURVQK-UHFFFAOYSA-N 0.000 description 2
- ILVYMPMYKKRSPO-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-4-amine Chemical compound NC1CC(C)(C)OC2=CC(OC)=CC=C21 ILVYMPMYKKRSPO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- JVPBOLPDUWAYAL-UHFFFAOYSA-N C=1C=C2OC(C)(C)CC(=NO)C2=CC=1C1=CC=C(Br)C=C1 Chemical compound C=1C=C2OC(C)(C)CC(=NO)C2=CC=1C1=CC=C(Br)C=C1 JVPBOLPDUWAYAL-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DHRNUGOZOYOZJI-UHFFFAOYSA-N NC1C(OC2=CC(=C(C=C2C1)F)N1CCCC1)(C)C Chemical compound NC1C(OC2=CC(=C(C=C2C1)F)N1CCCC1)(C)C DHRNUGOZOYOZJI-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FEWCTJHCXOHWNL-UHFFFAOYSA-N Roxatidine acetate hydrochloride Chemical compound Cl.CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 FEWCTJHCXOHWNL-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical group C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 2
- 229960005263 bucladesine Drugs 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- JUAMBJSJMUVASC-UHFFFAOYSA-N methyl 4-[ethylsulfonyl(pyridin-4-ylmethyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylate Chemical compound C1C(C)(C)OC2=CC=C(C(=O)OC)C=C2C1N(S(=O)(=O)CC)CC1=CC=NC=C1 JUAMBJSJMUVASC-UHFFFAOYSA-N 0.000 description 2
- BZBXTOXIAXZPQZ-UHFFFAOYSA-N n-(6-fluoro-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound FC1=CC=C2OC(C)(C)CC(=NO)C2=C1 BZBXTOXIAXZPQZ-UHFFFAOYSA-N 0.000 description 2
- APFSTNQKPGEBHQ-UHFFFAOYSA-N n-(6-fluoro-3,4-dihydro-2h-chromen-4-yl)ethanesulfonamide Chemical compound C1=C(F)C=C2C(NS(=O)(=O)CC)CCOC2=C1 APFSTNQKPGEBHQ-UHFFFAOYSA-N 0.000 description 2
- NIYGLRKUBPNXQS-FYYLOGMGSA-N n-[(4r)-1'-[(2r)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide Chemical compound C1CC2=CC(C#N)=CC=C2C[C@@H]1N(CC1)CCC11OC2=CC=C(NS(=O)(=O)C)C=C2[C@H](O)C1 NIYGLRKUBPNXQS-FYYLOGMGSA-N 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- XDUKPUDGTQCPFY-UHFFFAOYSA-N (2,5-dihydroxyphenyl) acetate Chemical compound CC(=O)OC1=CC(O)=CC=C1O XDUKPUDGTQCPFY-UHFFFAOYSA-N 0.000 description 1
- ZNOREXRHKZXVPC-UHFFFAOYSA-N (4-fluorophenyl) acetate Chemical compound CC(=O)OC1=CC=C(F)C=C1 ZNOREXRHKZXVPC-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PHFFZLIQGNLRRH-BYEGLACWSA-N 1-[(e)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]imidazolidine-2,4-dione;dihydrochloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O PHFFZLIQGNLRRH-BYEGLACWSA-N 0.000 description 1
- MREBEPTUUMTTIA-XYGWBWBKSA-N 1-[(z)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C/C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-XYGWBWBKSA-N 0.000 description 1
- SMKJTFWQUPHWOC-UHFFFAOYSA-N 1-[5-(4-bromophenyl)-2-hydroxyphenyl]ethanone Chemical group C1=C(O)C(C(=O)C)=CC(C=2C=CC(Br)=CC=2)=C1 SMKJTFWQUPHWOC-UHFFFAOYSA-N 0.000 description 1
- TYODDTFWIMEWAD-UHFFFAOYSA-N 1-ethoxy-3-iodopropane Chemical compound CCOCCCI TYODDTFWIMEWAD-UHFFFAOYSA-N 0.000 description 1
- BUZZUHJODKQYTF-UHFFFAOYSA-N 1-iodo-3-methylbutane Chemical compound CC(C)CCI BUZZUHJODKQYTF-UHFFFAOYSA-N 0.000 description 1
- BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 1
- LUBVCBITQHEVCJ-UHFFFAOYSA-N 1-trimethylsilylpyrrolidin-2-one Chemical compound C[Si](C)(C)N1CCCC1=O LUBVCBITQHEVCJ-UHFFFAOYSA-N 0.000 description 1
- WLDWSGZHNBANIO-UHFFFAOYSA-N 2',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC=C1O WLDWSGZHNBANIO-UHFFFAOYSA-N 0.000 description 1
- QYFREVFIVRIKQH-UHFFFAOYSA-N 2,2,6,7-tetramethyl-3,4-dihydrochromen-4-amine Chemical compound O1C(C)(C)CC(N)C2=C1C=C(C)C(C)=C2 QYFREVFIVRIKQH-UHFFFAOYSA-N 0.000 description 1
- AQAYMJHZXGZFBL-UHFFFAOYSA-N 2,2,6,7-tetramethyl-3h-chromen-4-one Chemical compound O1C(C)(C)CC(=O)C2=C1C=C(C)C(C)=C2 AQAYMJHZXGZFBL-UHFFFAOYSA-N 0.000 description 1
- IOSRRGXWFHYGDB-UHFFFAOYSA-N 2,2,6-trimethyl-3,4-dihydrochromen-3-amine Chemical compound O1C(C)(C)C(N)CC2=CC(C)=CC=C21 IOSRRGXWFHYGDB-UHFFFAOYSA-N 0.000 description 1
- CBXHPVYUFZUKPP-UHFFFAOYSA-N 2,2,6-trimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.O1C(C)(C)CC(N)C2=CC(C)=CC=C21 CBXHPVYUFZUKPP-UHFFFAOYSA-N 0.000 description 1
- TWTOMQLOZLAJFJ-UHFFFAOYSA-N 2,2-dimethyl-3-oxo-4h-chromene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2CC(=O)C(C)(C)OC2=C1 TWTOMQLOZLAJFJ-UHFFFAOYSA-N 0.000 description 1
- WXIOJWVNDKRWJF-UHFFFAOYSA-N 2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydrochromen-4-amine Chemical compound FC(F)(F)CCCOC1=CC=C2OC(C)(C)CC(N)C2=C1 WXIOJWVNDKRWJF-UHFFFAOYSA-N 0.000 description 1
- UKCXKMVTLZLMAX-UHFFFAOYSA-N 2,2-dimethyl-6-phenyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.C=1C=C2OC(C)(C)CC(N)C2=CC=1C1=CC=CC=C1 UKCXKMVTLZLMAX-UHFFFAOYSA-N 0.000 description 1
- NVWVWEWVLBKPSM-UHFFFAOYSA-N 2,4-difluorophenol Chemical compound OC1=CC=C(F)C=C1F NVWVWEWVLBKPSM-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- CEJINNSYZFLSCS-UHFFFAOYSA-N 2-hydroxy-1-(2-methylphenyl)ethanone Chemical compound CC1=CC=CC=C1C(=O)CO CEJINNSYZFLSCS-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- BNPWVUJOPCGHIK-UHFFFAOYSA-N 3,4-difluorophenol Chemical compound OC1=CC=C(F)C(F)=C1 BNPWVUJOPCGHIK-UHFFFAOYSA-N 0.000 description 1
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 1
- ILUQRRFVXAIYHN-UHFFFAOYSA-N 3-bromo-4-phenylphenol Chemical group BrC1=CC(O)=CC=C1C1=CC=CC=C1 ILUQRRFVXAIYHN-UHFFFAOYSA-N 0.000 description 1
- JNETYVLEGPSOFY-UHFFFAOYSA-N 3-bromopyrrolidine-2,5-dione Chemical compound BrC1CC(=O)NC1=O JNETYVLEGPSOFY-UHFFFAOYSA-N 0.000 description 1
- ZQXLIXHVJVAPLW-UHFFFAOYSA-N 3-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C(Cl)=C1 ZQXLIXHVJVAPLW-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical group C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OJYUPUBGYGZVNI-UHFFFAOYSA-N 4-[ethylsulfonyl(4,4,4-trifluorobutyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxamide Chemical compound C1=C(C(N)=O)C=C2C(N(CCCC(F)(F)F)S(=O)(=O)CC)CC(C)(C)OC2=C1 OJYUPUBGYGZVNI-UHFFFAOYSA-N 0.000 description 1
- FSZKETKIAORPOU-UHFFFAOYSA-N 4-[ethylsulfonyl(4,4,4-trifluorobutyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(N(CCCC(F)(F)F)S(=O)(=O)CC)CC(C)(C)OC2=C1 FSZKETKIAORPOU-UHFFFAOYSA-N 0.000 description 1
- KJOLLDGKGGVXHG-UHFFFAOYSA-N 4-[ethylsulfonyl(methyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(N(C)S(=O)(=O)CC)CC(C)(C)OC2=C1 KJOLLDGKGGVXHG-UHFFFAOYSA-N 0.000 description 1
- OKIIAJVCQJBKPU-UHFFFAOYSA-N 4-[ethylsulfonyl(pyridin-4-ylmethyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxamide Chemical compound C1C(C)(C)OC2=CC=C(C(N)=O)C=C2C1N(S(=O)(=O)CC)CC1=CC=NC=C1 OKIIAJVCQJBKPU-UHFFFAOYSA-N 0.000 description 1
- MPCWGJKKSRALIJ-UHFFFAOYSA-N 4-[ethylsulfonyl(pyridin-4-ylmethyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound C1C(C)(C)OC2=CC=C(C(O)=O)C=C2C1N(S(=O)(=O)CC)CC1=CC=NC=C1 MPCWGJKKSRALIJ-UHFFFAOYSA-N 0.000 description 1
- GDBUZIKSJGRBJP-UHFFFAOYSA-N 4-acetoxy benzoic acid Chemical compound CC(=O)OC1=CC=C(C(O)=O)C=C1 GDBUZIKSJGRBJP-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- PVKAIPMXFZNCDQ-UHFFFAOYSA-N 4-sulfonyl-2,3-dihydrochromen-2-amine Chemical group C1=CC=C2OC(N)CC(=S(=O)=O)C2=C1 PVKAIPMXFZNCDQ-UHFFFAOYSA-N 0.000 description 1
- PDCBSXRDMMRWRF-UHFFFAOYSA-N 5,6,7,8-tetramethyl-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=C(C)C(C)=C(C)C(C)=C21 PDCBSXRDMMRWRF-UHFFFAOYSA-N 0.000 description 1
- HTYRTGGIOAMLRR-UHFFFAOYSA-N 5-amino-4-hydroxybenzene-1,3-disulfonic acid Chemical compound NC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O HTYRTGGIOAMLRR-UHFFFAOYSA-N 0.000 description 1
- CYYQCHBLHSIWSN-UHFFFAOYSA-N 6,7-dichloro-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.ClC1=C(Cl)C=C2OC(C)(C)CC(N)C2=C1 CYYQCHBLHSIWSN-UHFFFAOYSA-N 0.000 description 1
- CQHBZGOGXXIFBT-UHFFFAOYSA-N 6,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.FC1=CC(F)=C2OC(C)(C)CC(N)C2=C1 CQHBZGOGXXIFBT-UHFFFAOYSA-N 0.000 description 1
- ZIAYCRDHSNHXOG-UHFFFAOYSA-N 6-(4-bromophenyl)-2,2-dimethyl-3h-chromen-4-one Chemical compound C=1C=C2OC(C)(C)CC(=O)C2=CC=1C1=CC=C(Br)C=C1 ZIAYCRDHSNHXOG-UHFFFAOYSA-N 0.000 description 1
- ICCUWDQOENJRLO-UHFFFAOYSA-N 6-ethyl-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.O1C(C)(C)CC(N)C2=CC(CC)=CC=C21 ICCUWDQOENJRLO-UHFFFAOYSA-N 0.000 description 1
- LLWCBPNSRBRTGN-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-amine Chemical compound FC1=CC=C2OC(C)(C)CC(N)C2=C1 LLWCBPNSRBRTGN-UHFFFAOYSA-N 0.000 description 1
- ZKJHJJCSEUDVCQ-UHFFFAOYSA-N 6-fluoro-2,2-dimethyl-7-pyrrolidin-1-yl-3,4-dihydrochromen-4-amine;dihydrochloride Chemical compound Cl.Cl.C1=C2OC(C)(C)CC(N)C2=CC(F)=C1N1CCCC1 ZKJHJJCSEUDVCQ-UHFFFAOYSA-N 0.000 description 1
- SWBBIJZMIGAZHW-UHFFFAOYSA-N 6-fluoro-2,3-dihydrochromen-4-one Chemical compound O1CCC(=O)C2=CC(F)=CC=C21 SWBBIJZMIGAZHW-UHFFFAOYSA-N 0.000 description 1
- VHMBQKMHABXVJN-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromen-4-amine;hydrochloride Chemical compound Cl.C1=C(F)C=C2C(N)CCOC2=C1 VHMBQKMHABXVJN-UHFFFAOYSA-N 0.000 description 1
- FYXPWIUHWKJSSP-UHFFFAOYSA-N 6-methoxy-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.O1C(C)(C)CC(N)C2=CC(OC)=CC=C21 FYXPWIUHWKJSSP-UHFFFAOYSA-N 0.000 description 1
- QTUMYGSIHORDJL-UHFFFAOYSA-N 7-chloro-6-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-amine;hydrochloride Chemical compound Cl.FC1=C(Cl)C=C2OC(C)(C)CC(N)C2=C1 QTUMYGSIHORDJL-UHFFFAOYSA-N 0.000 description 1
- QXKXYXNEOUCMIY-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3h-chromen-4-one Chemical compound O=C1CC(C)(C)OC2=CC(OC)=CC=C21 QXKXYXNEOUCMIY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- YNPDFBFVMJNGKZ-UHFFFAOYSA-N BTB10270 Natural products CC(=O)C1=CC(C)=CC=C1O YNPDFBFVMJNGKZ-UHFFFAOYSA-N 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- WBBBEAQRMGIIIW-UHFFFAOYSA-N C1=C2OC(C)(C)CC(=NO)C2=CC(F)=C1N1CCCC1 Chemical compound C1=C2OC(C)(C)CC(=NO)C2=CC(F)=C1N1CCCC1 WBBBEAQRMGIIIW-UHFFFAOYSA-N 0.000 description 1
- DYUITHUGQNOFAT-UHFFFAOYSA-N C1=CC=C2OC(C)(C)C(N(CC)S(=O)(=O)CC)CC2=C1 Chemical compound C1=CC=C2OC(C)(C)C(N(CC)S(=O)(=O)CC)CC2=C1 DYUITHUGQNOFAT-UHFFFAOYSA-N 0.000 description 1
- NGZTWVDNOAMJMW-UHFFFAOYSA-N CC(C)(CC(c1c2)N(C)CS(N(C)C)(=O)=O)Oc1ccc2F Chemical compound CC(C)(CC(c1c2)N(C)CS(N(C)C)(=O)=O)Oc1ccc2F NGZTWVDNOAMJMW-UHFFFAOYSA-N 0.000 description 1
- HCSVOPUKSHLHNZ-UHFFFAOYSA-N CC(C)(CC1N(C)S(C)(=O)=O)Oc(cc2)c1cc2C(OC)=O Chemical compound CC(C)(CC1N(C)S(C)(=O)=O)Oc(cc2)c1cc2C(OC)=O HCSVOPUKSHLHNZ-UHFFFAOYSA-N 0.000 description 1
- RBYOFFLCBCOJRL-UHFFFAOYSA-N CC(C)CCN(C1c(cc(C)cc2)c2OC(C)(C)C1)[S](C)(C)(=O)=O Chemical compound CC(C)CCN(C1c(cc(C)cc2)c2OC(C)(C)C1)[S](C)(C)(=O)=O RBYOFFLCBCOJRL-UHFFFAOYSA-N 0.000 description 1
- RZVMHSHTORPPOU-UHFFFAOYSA-N CC(C)S(N(C)C1c(cc(cc2)C(O)=O)c2OC(C)(C)C1)(=O)=O Chemical compound CC(C)S(N(C)C1c(cc(cc2)C(O)=O)c2OC(C)(C)C1)(=O)=O RZVMHSHTORPPOU-UHFFFAOYSA-N 0.000 description 1
- VBOFMHSWKDASBA-UHFFFAOYSA-N CCN(C1c(ccc(OC)c2)c2OC(C)(C)C1)S(CC)(=O)=O Chemical compound CCN(C1c(ccc(OC)c2)c2OC(C)(C)C1)S(CC)(=O)=O VBOFMHSWKDASBA-UHFFFAOYSA-N 0.000 description 1
- HEMFIXVXTDRVAN-UHFFFAOYSA-N CCN(C1c2cc(F)ccc2OC(C)(C)C1)S(CC)(=O)=O Chemical compound CCN(C1c2cc(F)ccc2OC(C)(C)C1)S(CC)(=O)=O HEMFIXVXTDRVAN-UHFFFAOYSA-N 0.000 description 1
- QPYFDTYIDKWDEL-UHFFFAOYSA-N CCS(N(C)C1c(cc(cc2)F)c2OC2(CCCC2)C1)(=O)=O Chemical compound CCS(N(C)C1c(cc(cc2)F)c2OC2(CCCC2)C1)(=O)=O QPYFDTYIDKWDEL-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHQNBJIOSSUFGQ-UHFFFAOYSA-N Cl.NC1CC(OC2=CC(=C(C=C12)C)C)(C)C Chemical compound Cl.NC1CC(OC2=CC(=C(C=C12)C)C)(C)C GHQNBJIOSSUFGQ-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- CTLUYYHOGYSBSH-UHFFFAOYSA-N FC1=C(Cl)C=C2OC(C)(C)CC(=NO)C2=C1 Chemical compound FC1=C(Cl)C=C2OC(C)(C)CC(=NO)C2=C1 CTLUYYHOGYSBSH-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- GDPBZFJOCVCFBX-UHFFFAOYSA-N N-(2,2-dimethyl-3H-chromen-4-ylidene)hydroxylamine Chemical compound C1=CC=C2OC(C)(C)CC(=NO)C2=C1 GDPBZFJOCVCFBX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- QBDYHZFUNFSHHA-UHFFFAOYSA-N NC1C(OC2=CC=C(C=C2C1)C1=CC=CC=C1)(C)C Chemical compound NC1C(OC2=CC=C(C=C2C1)C1=CC=CC=C1)(C)C QBDYHZFUNFSHHA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- LOVYYPPJQRFHKS-UHFFFAOYSA-N O1C(C)(C)CC(=NO)C2=C1C=C(OC)C(OC)=C2 Chemical compound O1C(C)(C)CC(=NO)C2=C1C=C(OC)C(OC)=C2 LOVYYPPJQRFHKS-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002369 angiotensin antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000006172 aromatic nitration reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001562 benzopyrans Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- WEDIIKBPDQQQJU-UHFFFAOYSA-N butane-1-sulfonyl chloride Chemical compound CCCCS(Cl)(=O)=O WEDIIKBPDQQQJU-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 229940082657 digitalis glycosides Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002599 gastric fundus Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- ZRPNVMHNPXWAPM-UHFFFAOYSA-N methyl 4-[dimethylsulfamoyl(methyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylate Chemical compound O1C(C)(C)CC(N(C)S(=O)(=O)N(C)C)C2=CC(C(=O)OC)=CC=C21 ZRPNVMHNPXWAPM-UHFFFAOYSA-N 0.000 description 1
- OKJRHSWBPBITBK-UHFFFAOYSA-N methyl 4-[ethylsulfonyl(4,4,4-trifluorobutyl)amino]-2,2-dimethyl-3,4-dihydrochromene-6-carboxylate Chemical compound C1=C(C(=O)OC)C=C2C(N(CCCC(F)(F)F)S(=O)(=O)CC)CC(C)(C)OC2=C1 OKJRHSWBPBITBK-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- GKBAWFXOKVYCEM-UHFFFAOYSA-N n-(2,2,6,7-tetramethyl-3,4-dihydrochromen-3-yl)ethanesulfonamide Chemical compound CC1=C(C)C=C2OC(C)(C)C(NS(=O)(=O)CC)CC2=C1 GKBAWFXOKVYCEM-UHFFFAOYSA-N 0.000 description 1
- QWRFDVPFTMYBQB-UHFFFAOYSA-N n-(2,2,6,7-tetramethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound O1C(C)(C)CC(=NO)C2=C1C=C(C)C(C)=C2 QWRFDVPFTMYBQB-UHFFFAOYSA-N 0.000 description 1
- OWGYOBHNMLWQDC-UHFFFAOYSA-N n-(2,2,6-trimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound O1C(C)(C)CC(=NO)C2=CC(C)=CC=C21 OWGYOBHNMLWQDC-UHFFFAOYSA-N 0.000 description 1
- AMODJIKAKVHUFI-UHFFFAOYSA-N n-(2,2-dimethyl-6-phenyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound C=1C=C2OC(C)(C)CC(=NO)C2=CC=1C1=CC=CC=C1 AMODJIKAKVHUFI-UHFFFAOYSA-N 0.000 description 1
- CQFRPHUTZHSMOP-UHFFFAOYSA-N n-(6,7-dichloro-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound ClC1=C(Cl)C=C2OC(C)(C)CC(=NO)C2=C1 CQFRPHUTZHSMOP-UHFFFAOYSA-N 0.000 description 1
- FJBRRGPIEUTHPB-UHFFFAOYSA-N n-(6,8-difluoro-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound FC1=CC(F)=C2OC(C)(C)CC(=NO)C2=C1 FJBRRGPIEUTHPB-UHFFFAOYSA-N 0.000 description 1
- WCSSTKFXFSZDMA-UHFFFAOYSA-N n-(6-cyano-2,2-dimethyl-3,4-dihydrochromen-4-yl)-n-(4,4,4-trifluorobutyl)ethanesulfonamide Chemical compound C1=C(C#N)C=C2C(N(CCCC(F)(F)F)S(=O)(=O)CC)CC(C)(C)OC2=C1 WCSSTKFXFSZDMA-UHFFFAOYSA-N 0.000 description 1
- YUBRIOSETGSKGV-UHFFFAOYSA-N n-(6-ethyl-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound O1C(C)(C)CC(=NO)C2=CC(CC)=CC=C21 YUBRIOSETGSKGV-UHFFFAOYSA-N 0.000 description 1
- HEQPLVRXTJYCRD-UHFFFAOYSA-N n-(6-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl)ethanesulfonamide Chemical compound C1=C(F)C=C2C(NS(=O)(=O)CC)CC(C)(C)OC2=C1 HEQPLVRXTJYCRD-UHFFFAOYSA-N 0.000 description 1
- OOCJVKPPHVLPIM-UHFFFAOYSA-N n-(6-fluoro-2,3-dihydrochromen-4-ylidene)hydroxylamine Chemical compound C1=C(F)C=C2C(=NO)CCOC2=C1 OOCJVKPPHVLPIM-UHFFFAOYSA-N 0.000 description 1
- PXSVMKRGPKFNRM-UHFFFAOYSA-N n-(6-methoxy-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound O1C(C)(C)CC(=NO)C2=CC(OC)=CC=C21 PXSVMKRGPKFNRM-UHFFFAOYSA-N 0.000 description 1
- GQYWWZISGWDNRQ-UHFFFAOYSA-N n-(7-methoxy-2,2-dimethyl-3,4-dihydrochromen-3-yl)ethanesulfonamide Chemical compound C1=C(OC)C=C2OC(C)(C)C(NS(=O)(=O)CC)CC2=C1 GQYWWZISGWDNRQ-UHFFFAOYSA-N 0.000 description 1
- XHFLQLXESPFWLE-UHFFFAOYSA-N n-(7-methoxy-2,2-dimethyl-3h-chromen-4-ylidene)hydroxylamine Chemical compound ON=C1CC(C)(C)OC2=CC(OC)=CC=C21 XHFLQLXESPFWLE-UHFFFAOYSA-N 0.000 description 1
- BASAUWFNEPUJDQ-ZMBIFBSDSA-N n-[1'-[(2r)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-6-yl]methanesulfonamide;hydron;chloride Chemical compound Cl.C1CC2=CC(C#N)=CC=C2C[C@@H]1N(CC1)CCC11OC2=CC=C(NS(=O)(=O)C)C=C2C(=O)C1 BASAUWFNEPUJDQ-ZMBIFBSDSA-N 0.000 description 1
- XRKQMIFKHDXFNQ-UHFFFAOYSA-N n-cyclohexyl-n-ethylcyclohexanamine Chemical compound C1CCCCC1N(CC)C1CCCCC1 XRKQMIFKHDXFNQ-UHFFFAOYSA-N 0.000 description 1
- QSPPRYLTQFCUCH-UHFFFAOYSA-N n-methylethanesulfonamide Chemical compound CCS(=O)(=O)NC QSPPRYLTQFCUCH-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- KQOCMRACUONAJY-UHFFFAOYSA-N spiro[chromene-2,4'-piperidine] Chemical compound C1CNCCC21C=CC1=CC=CC=C1O2 KQOCMRACUONAJY-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19619614A DE19619614A1 (de) | 1996-05-15 | 1996-05-15 | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19639462:7 | 1996-09-26 | ||
| DE1996139462 DE19639462A1 (de) | 1996-09-26 | 1996-09-26 | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19619614:0 | 1996-09-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH1067772A JPH1067772A (ja) | 1998-03-10 |
| JPH1067772A5 JPH1067772A5 (enExample) | 2005-04-07 |
| JP4234798B2 true JP4234798B2 (ja) | 2009-03-04 |
Family
ID=26025736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13798497A Expired - Fee Related JP4234798B2 (ja) | 1996-05-15 | 1997-05-14 | スルホンアミド−置換クロマン、それらの製造法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0807629B1 (enExample) |
| JP (1) | JP4234798B2 (enExample) |
| KR (1) | KR100547921B1 (enExample) |
| CN (1) | CN1204134C (enExample) |
| AR (2) | AR007115A1 (enExample) |
| AT (1) | ATE260909T1 (enExample) |
| AU (1) | AU711986B2 (enExample) |
| BR (1) | BR9703161A (enExample) |
| CA (1) | CA2205477A1 (enExample) |
| CZ (1) | CZ149497A3 (enExample) |
| DE (1) | DE59711352D1 (enExample) |
| DK (1) | DK0807629T3 (enExample) |
| ES (1) | ES2218617T3 (enExample) |
| HR (1) | HRP970255B1 (enExample) |
| HU (1) | HUP9700903A3 (enExample) |
| IL (1) | IL120827A (enExample) |
| NO (1) | NO315556B1 (enExample) |
| NZ (1) | NZ314800A (enExample) |
| PL (1) | PL191330B1 (enExample) |
| PT (1) | PT807629E (enExample) |
| SK (1) | SK283837B6 (enExample) |
| TR (1) | TR199700369A2 (enExample) |
| TW (1) | TW496866B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ329200A (en) * | 1996-12-16 | 1999-05-28 | Hoechst Ag | Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments |
| DE19705133A1 (de) * | 1997-02-11 | 1998-08-13 | Hoechst Ag | Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19706675A1 (de) * | 1997-02-20 | 1998-08-27 | Hoechst Ag | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| EP0895994A3 (de) | 1997-08-05 | 1999-12-15 | Hoechst Marion Roussel Deutschland GmbH | Sulfonamid-substituierte Pyranopyridine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19742509A1 (de) * | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE19742508A1 (de) * | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE19748469A1 (de) * | 1997-11-03 | 1999-05-06 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| WO2000012077A1 (en) * | 1998-09-01 | 2000-03-09 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
| DE19858253A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
| US7368582B2 (en) | 2003-10-17 | 2008-05-06 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them |
| NZ585606A (en) * | 2004-03-23 | 2011-11-25 | Nissan Chemical Ind Ltd | Tricyclic benzopyran compound as anti-arrhythmic agents |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| CN102414213B (zh) * | 2009-04-30 | 2014-12-24 | 日产化学工业株式会社 | 三环苯并吡喃化合物的新的晶形及其制造方法 |
| TWI583677B (zh) | 2012-09-21 | 2017-05-21 | 日本臟器製藥股份有限公司 | 香豆素衍生物 |
| CN103012380B (zh) * | 2013-01-10 | 2015-03-04 | 山东大学 | 一种色满类化合物及其制备方法与应用 |
| JP6089055B2 (ja) * | 2014-03-20 | 2017-03-01 | 日本臓器製薬株式会社 | クマリン誘導体を含有する医薬 |
| AR117169A1 (es) | 2018-11-28 | 2021-07-14 | Bayer Ag | (tio)amidas de piridazina como compuestos fungicidas |
| JP2023538713A (ja) | 2020-05-06 | 2023-09-11 | バイエル、アクチエンゲゼルシャフト | 殺真菌性化合物としてのピリジン（チオ）アミド |
| WO2021228734A1 (en) | 2020-05-12 | 2021-11-18 | Bayer Aktiengesellschaft | Triazine and pyrimidine (thio)amides as fungicidal compounds |
| WO2021233861A1 (en) | 2020-05-19 | 2021-11-25 | Bayer Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
| JP7760531B2 (ja) | 2020-05-27 | 2025-10-27 | バイエル、アクチエンゲゼルシャフト | 活性化合物の組合せ物 |
| EP4426677A1 (en) | 2021-11-03 | 2024-09-11 | Bayer Aktiengesellschaft | Bis(hetero)aryl thioether (thio)amides as fungicidal compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3737195A1 (de) * | 1987-11-03 | 1989-05-18 | Bayer Ag | Chromanderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| FR2639349B1 (fr) * | 1988-11-23 | 1991-02-22 | Sanofi Sa | Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant |
| US5104890A (en) * | 1989-03-28 | 1992-04-14 | Fujisawa Pharmaceutical Company, Ltd. | Benzopyran derivatives and processes for preparation thereof |
-
1997
- 1997-05-13 SK SK603-97A patent/SK283837B6/sk unknown
- 1997-05-13 ES ES97107775T patent/ES2218617T3/es not_active Expired - Lifetime
- 1997-05-13 AT AT97107775T patent/ATE260909T1/de not_active IP Right Cessation
- 1997-05-13 NZ NZ314800A patent/NZ314800A/xx unknown
- 1997-05-13 DE DE59711352T patent/DE59711352D1/de not_active Expired - Lifetime
- 1997-05-13 HR HR970255A patent/HRP970255B1/xx not_active IP Right Cessation
- 1997-05-13 EP EP97107775A patent/EP0807629B1/de not_active Expired - Lifetime
- 1997-05-13 PT PT97107775T patent/PT807629E/pt unknown
- 1997-05-13 DK DK97107775T patent/DK0807629T3/da active
- 1997-05-13 CN CNB971115400A patent/CN1204134C/zh not_active Expired - Fee Related
- 1997-05-13 TW TW086106326A patent/TW496866B/zh not_active IP Right Cessation
- 1997-05-13 AU AU20806/97A patent/AU711986B2/en not_active Ceased
- 1997-05-13 AR ARP970101998A patent/AR007115A1/es not_active Application Discontinuation
- 1997-05-13 TR TR97/00369A patent/TR199700369A2/xx unknown
- 1997-05-14 CZ CZ971494A patent/CZ149497A3/cs unknown
- 1997-05-14 JP JP13798497A patent/JP4234798B2/ja not_active Expired - Fee Related
- 1997-05-14 BR BR9703161A patent/BR9703161A/pt not_active Application Discontinuation
- 1997-05-14 NO NO19972211A patent/NO315556B1/no unknown
- 1997-05-14 IL IL12082797A patent/IL120827A/en not_active IP Right Cessation
- 1997-05-15 CA CA002205477A patent/CA2205477A1/en not_active Abandoned
- 1997-05-15 KR KR1019970018635A patent/KR100547921B1/ko not_active Expired - Fee Related
- 1997-05-15 PL PL319995A patent/PL191330B1/pl unknown
- 1997-05-15 HU HU9700903A patent/HUP9700903A3/hu unknown
- 1997-11-26 AR ARP970105574A patent/AR010314A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4234798B2 (ja) | スルホンアミド−置換クロマン、それらの製造法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬 | |
| CA2811154A1 (en) | Prostaglandin transporter inhibitors and uses thereof | |
| HUP9800374A2 (en) | Sulfonamide-substituted chromanes process for producing them, their use as medicines and pharmaceutical composition containing them | |
| EP0906911B1 (de) | Sulfonamid-substituierte Chromane (K+Kanal-Blocker), Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen | |
| US6191164B1 (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them | |
| TW593307B (en) | Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them | |
| ES2234044T3 (es) | Compuestos anulares de siete miembros, condensados sustituidos con sulfonamido con actividad bloqueante del canal de potasio. | |
| JP4331809B2 (ja) | スルホンアミド置換−５員縮合環化合物、医薬としてのその使用およびそれを含有する医薬製剤 | |
| US5955607A (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparations comprising them | |
| EP1633742A1 (de) | Indol-derivate als serotonin-wiederaufnahme-inhibitoren | |
| JP2003515593A (ja) | ３−置換−４−アリールキノリン−２−オン誘導体の製造 | |
| MXPA97003534A (en) | Chromants replaced with sulfonamide, procedure for preparation, employment as a medicinal or diagnostic agent, and as a medication that conti | |
| RU2182149C2 (ru) | Кристаллический (-)-3r,4r-транс-7-метокси-2,2-диметил-3-фенил-4-{4-[2-(пирролидин-1-ил)этокси]фенил}хроман, гидрофумарат, способ его получения, фармацевтическая композиция, способ уменьшения или предупреждения разрежения кости | |
| JPH10218855A (ja) | スルホンアミド置換化合物、それらの製造法、薬剤または診断剤としてのそれらの使用およびそれらを含有する薬剤 | |
| DE19619614A1 (de) | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
| DE19639462A1 (de) | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament | |
| EP1001953A1 (en) | Cristalline ( - ) - 3r,4r -trans-7-methoxy -2,2-dimethyl-3-phenyl-4- 4- 2-(pyrrolidin-1-yl)ethoxy] phenyl chromane, hydrogen maleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040510 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081009 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081118 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081212 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |